RIGL Stock - Rigel Pharmaceuticals, Inc.
Unlock GoAI Insights for RIGL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $179.28M | $116.88M | $120.24M | $149.24M | $108.62M |
| Gross Profit | $160.63M | $109.77M | $118.49M | $148.15M | $107.73M |
| Gross Margin | 89.6% | 93.9% | 98.5% | 99.3% | 99.2% |
| Operating Income | $24.19M | $-20,491,000 | $-55,550,000 | $-12,496,000 | $-28,973,000 |
| Net Income | $17.48M | $-25,091,000 | $-58,573,000 | $-17,914,000 | $-29,744,000 |
| Net Margin | 9.8% | -21.5% | -48.7% | -12.0% | -27.4% |
| EPS | $0.99 | $-1.44 | $-3.40 | $-1.10 | $-1.80 |
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 5th 2025 | Jefferies | Upgrade | Buy | $42 |
| April 3rd 2023 | Piper Sandler | Resumed | Neutral | $2 |
| June 9th 2022 | Citigroup | Downgrade | Neutral | - |
| June 8th 2022 | Piper Sandler | Downgrade | Neutral | $1← $7 |
| June 8th 2022 | Cantor Fitzgerald | Downgrade | Neutral | $1← $6 |
Earnings History & Surprises
RIGLEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $1.08 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.93 | $1.46 | +57.0% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $1.97 | $3.28 | +66.5% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $0.14 | $0.63 | +350.0% | ✓ BEAT |
Q1 2025 | Mar 4, 2025 | $0.30 | $0.80 | +166.7% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $0.06 | $0.70 | +1066.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.37 | $-0.06 | +83.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.30 | $-0.50 | -66.7% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $0.02 | $0.04 | +100.0% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.70 | $-0.30 | +57.1% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-0.80 | $-0.40 | +50.0% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $-0.90 | $-0.80 | +11.1% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $-0.70 | $0.10 | +114.3% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-1.30 | $-1.10 | +15.4% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-1.20 | $-0.80 | +33.3% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $-1.20 | $-1.60 | -33.3% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-1.30 | $-1.30 | 0.0% | = MET |
Q4 2021 | Nov 2, 2021 | $-1.00 | $-1.20 | -20.0% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $-1.10 | $-0.80 | +27.3% | ✓ BEAT |
Latest News
Reported Sunday, Rigel Presents Updated Phase 1b R289 Data In Lower-Risk MDS At ASH 2025, Showing 33% RBC-TI At ≥500 Mg With Favorable Tolerability
📈 PositiveRigel Pharmaceuticals Reports Publication In The Journal Of Hematology & Oncology; 5-Year Data Showing Durable Efficacy And Manageable Safety For REZLIDHIA In R/R mIDH1 AML
📈 PositiveJefferies Upgrades Rigel Pharmaceuticals to Buy, Raises Price Target to $42
📈 PositiveRigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats
📈 PositiveCantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $38
➖ NeutralRigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveRigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveRigel Pharmaceuticals GAAP EPS of $1.46 beats by $0.56, revenue of $69.46M beats by $7.58M
📈 PositiveRigel Pharmaceuticals Raises FY2025 Sales Guidance from $210.000M-$220.000M to $285.000M-$290.000M vs $281.095M Est
📈 PositiveRigel Pharmaceuticals Q3 EPS $1.46 Beats $0.84 Estimate, Sales $69.462M Beat $61.880M Estimate
📈 PositiveRigel Pharma Announces First Patient Enrolled In Dose Expansion Phase Of Ongoing Phase 1b Study Of R2891 In Patients With R/R Lower-Risk MDS, Earlier Today
📈 PositiveHC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
📈 PositiveFrequently Asked Questions about RIGL
What is RIGL's current stock price?
What is the analyst price target for RIGL?
What sector is Rigel Pharmaceuticals, Inc. in?
What is RIGL's market cap?
Does RIGL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RIGL for comparison